Xelpros is owned by Sun Pharm.
Xelpros contains Latanoprost.
Xelpros has a total of 2 drug patents out of which 0 drug patents have expired.
Xelpros was authorised for market use on 12 September, 2018.
Xelpros is available in emulsion;ophthalmic dosage forms.
Xelpros can be used as reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The generics of Xelpros are possible to be released after 12 September, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9539262||SUN PHARM||Ophthalmic composition comprising a prostaglandin|| |
(5 years from now)
|US9629852||SUN PHARM||Ophthalmic composition comprising a prostaglandin|| |
(6 years from now)
Market Authorisation Date: 12 September, 2018
Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic